Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

A man with both skin lesions and lung cancer improved quickly with chemotherapy, suggesting the skin condition might be a reaction to immune system injury.

Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.

Expanding CD4+ Tregs can stop hair loss in alopecia areata.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

Ritlecitinib is effective for long-term treatment of severe alopecia areata.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Dupilumab may help treat alopecia areata without needing high IgE levels.

Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.

Bimekizumab effectively treated a man's chronic beard hair loss.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Omalizumab may cause temporary hair loss, especially in women aged 18-60.

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Targeting amphiregulin may improve treatment for fibrosis and cancer.

Intralesional methotrexate effectively treats patchy alopecia areata by reducing inflammation.

Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

High MUC-18/MCAM levels in blood indicate a worse outlook for melanoma patients.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

Etanercept effectively treated a severe skin condition when other treatments failed.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.